< Back to previous page


A gene editing strategy for refractory CFTR mutations causing cystic fibrosis.

The goal of our project is to develop CRISPR-Cas gene editing therapy for CFTR mutations refractory to current CFTR modulators. A functional rescue will be assessed in human CF intestinal organoïds and airway cultures.

Date:3 Sep 2020  →  Today
Keywords:CRISPR-Cas gene editing therapy, cystic fibrosis
Disciplines:Respiratory medicine